Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: Application to a pharmacokinetic study

Biomedical Chromatography

Volumn 23, Issue 1, 2009, Pages 71-80

  Tang, Cheng ^a   Bi, Hui Chang ^a   Zhong, Guo Ping ^a   Chen, Xiao ^a   Huang, Zhi Ying ^a   Huang, Min ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Liquid chromatography tandem mass spectrometry; Mifepristone; Monodemethyl mifepristone; Pharmacokinetics

Indexed keywords

HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHASE SEPARATION; PLASMA (HUMAN); QUALITY CONTROL;

HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LEVONORGESTREL; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; MIFEPRISTONE; MONODEMETHYL-MIFEPRISTONE; PHARMACOKINETIC STUDIES;

PHARMACOKINETICS;

DRUG METABOLITE; LEVONORGESTREL; MIFEPRISTONE; NORMIFEPRISTONE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; ELECTROSPRAY; FEMALE; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; STANDARDIZATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDITY;

EID: 59949090514     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1086     Document Type: Article

References (22)

1. Bi HC, Zhong GP, Zhou SF, Chen X and Huang M. Determination of adefovir in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Communications in Mass Spectrometry 2005; 19: 2911.
2. FDA. Guidance for Industry Bioanalytical Method Validation, May 2001.
3. Földesi I, Falkay G and Kovács L. Determination of RU486 (Mifepristone) in blood by radioreceptorassay: a pharmacokinetic study. Contraception 1996; 54: 27.
4. Guo Z, Chu C, Yin G, He M, Fu K and Wu J. An HPLC method for the determination of ng mifepristone in human plasma. Journal of Chromatography B 2006; 832: 181.
5. Guo Z, Wang S, Wei D and Zhai J. Development of a high-performance liquid chromatographic method for the determination of mifepristone in human plasma using norethisterone as an internal standard: application to pharmacokinetic study. Contraception 2007a; 76: 228.
6. Guo Z, Wei D, Yin G, Wang S, Zhao S, Chu Y and Zhai J. Simultaneous determination of rivanol and mifepristone in human plasma by a HPLC-UV method with solid-phase extraction. Journal of Chromatography B 2007b; 856: 312.
7. He CH, Shi YE, Ye ZH, Zhang GQ, Jiang NX, Van Look PF and Fotherby K. Pharmacokinetic study of orally administered RU 486 in non-pregnant women. Contraception 1989; 40: 449.
8. Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clinical Pharmacokinetics 1997; 33: 17.
9. Heikinheimo O. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. Journal of Steroid Biochemistry and Molecular Biology 1989; 32: 21.
10. Heikinheimo O, Tevilin M, Shoupe D, Croxxato M and Lähteenmak̈i P. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. Contraception 1986; 34: 613.
11. Heikinheimo O, Kontula K, Croxxato M, Spitz I, Luukkainen T and Lähteenmäki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. Journal of Steroid Biochemistry and Molecular Biology 1987; 26: 279.
12. Heikinheimo O, Kekkonen R and Lähteenmäki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action. Contraception 2003; 68: 421.
13. Kawai S, Nieman LK, Brandon DD, Udelsman R, Loriaux DL and Chrousos GP. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone RU 486 in man. Journal of Pharmacology and Experimental Therapeutics 1987; 241: 401.
14. Kekkonen R, Heikinheimo O, Mandelin E and Lahteenmaki P. Pharmacokinetics of mifepristone after low oral doses. Contraception 1996; 54: 229.
15. Lähteenmäki P, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L and Luukkainen T. Pharmacokinetics and metabolism of RU 486. Journal of Steroid Biochemistry and Molecular Biology 1987; 27: 859.
16. Leminen R, Ranta S, Hertzen von H, Oehler J and Heikinheimo O. Pharmacokinetics of 10 mg of mifepristone. Contraception 2003; 68: 427.
17. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019.
18. Sarkar NN. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. European Journal of Obstetrics & Gynecology and Reproductive Biology 2002; 101: 113.
19. Shi YE, Ye ZH, He CH, Zhang GQ, Xu JQ, Van Look PF and Fotherby K. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception 1993; 48: 133.
20. Stith C and Hussain MD. Determination of mifepristone levels in wild canid serum using liquid chromatography, Journal of Chromatography B 2003; 794: 9.
21. Wang J, Shi W, Zhang G and Bai X. Tissue and serum levels of steroid hormones and RU 486 after administration of mifepristone. Contraception 1994; 49: 245.
22. Wei Y, Zhang M, Wang G, Zhao Z and Shao Q. Pharmacokinetics of mifepristone after low oral dose in healthy Chinese women. Chinese Journal of Clinical Pharmacology 2003; 19: 430.